Placeholder

Pink Ribbons of Opportunity

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

Tremendous progress has been made in treating breast cancer. Survival rates have increased because of earlier diagnosis and new therapies, including hormonal products and biologics. Still, about 40,000 patients die every year from breast cancer, and the estimated lifetime risk of breast cancer has gone up gradually over the past several decades. The National Cancer Institute estimates that, based on current rates, 13.2% of women born today (1 in 8 women) will be diagnosed with breast cancer at some time in their lives.
These statistics indicate that there is still substantial unmet need and opportunities for companies that can bring safe and effective products to the market that also have fewer side effects…

Sidebars:
Factors Impacting the Breast Cancer Market
Breast Cancer Incidence and Death by Race and Ethnicity, U.S. 1998-2002
Breast Cancer Facts

Experts on this Topic
Michel Azoulay, M.D. Engagement Manager, IMS Health, Plymouth Meeting, Pa.; IMS Health is a global source for pharmaceutical market intelligence. For more information, visit imshealth.com.
Paul Boyce. VP, Client Services, TNS Healthcare, New York; TNS Healthcare, which is part of TNS, provides globally consistent solutions and custom advisory services to support product introductions; brand, treatment and sales performance optimization; and professional and DTC promotional tracking. For more information, visit tns-global.com.
David Epstein. President and CEO, Novartis Oncology, East Hanover, N.J.; Novartis Oncology, part of Novartis Pharmaceuticals Corp., offers treatments for cancers that range from breast cancer to leukemia to bone cancer to carcinoid tumors. For more information, visit us.novartisoncology.com.
Gretchen Goffe. VP of Planning, GSW Worldwide, and Principal Partner, Pink Tank, Westerville, Ohio; GSW Worldwide, an inVentiv Health company, is one of the largest healthcare advertising agencies in the world with offices in 13 major global markets. For more information, visit gsw-w.com.
Paolo Paoletti, M.D. Senior VP of the Oncology Medicine Development Center at GlaxoSmithKline, Philadelphia; GlaxoSmithKline discovers, develops, and delivers innovative prescription medicines, vaccines, and other products. For more information, visit us.gsk.com.
Paul Plourd, M.D. Senior Director of Oncology at AstraZeneca Pharmaceuticals LP, Wilmington, Del.; AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. For more information, visit astrazeneca-us.com.
David Schenkein, M.D. VP of Clinical Oncology and Hematology, Genentech Inc., South San Francisco, Calif.; Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics. For more information, visit gene.com.

FEEDBACK